Now, Sodhi and his fellow researchers have identified the accumulation of a hypoxia-inducible factor 1-alpha (HIF-1-alpha), ...

Q3 2024 Earnings Call Transcript November 6, 2024 Arcus Biosciences, Inc. beats earnings expectations. Reported EPS is $-1, ...

Welireg, which is also a hypoxia-inducible factor-2 alpha (HIF-2a) inhibitor, won its second FDA approval in relapsed or refractory renal cell carcinoma in December. The therapy was initially ...

Gen Alpha, or those born after 2010, have developed their own terminology from 'skibidi' to 'fanum tax' Getty Gen Alpha have their own grasp on vocabulary that elder generations may call "sus ...

HIF-2α (hypoxia inducible factor 2 alpha) is an oxygen-sensing protein that is highly dysregulated in ccRCC. Management believes that cas has the potential to be more effective than Merck’s HIF ...

Exelixis, Inc. EXEL reported better-than-expected third-quarter results. Its shares have risen following the announcement.

A new generation has emerged: Generation Alpha. While the official age range for these youngsters is still heavily up for debate (some maintain the generation began in 2012 and runs through 2024 ...

“These data support the potential for casdatifan to be a best-in-class HIF-2a inhibitor for the treatment of ccRCC. We look forward to initiating our first Phase 3 study for casdatifan, PEAK ...

Both the companies will also evaluate zanzalintinib with Merck’s oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor Welireg (belzutifan) in a phase I/II study and two phase III studies ...

The data being presented include a growing body of evidence supporting the potential of casdatifan as a best-in-class HIF-2a inhibitor for the treatment of ccRCC. The oral presentation will ...